4D Molecular Therapeutics (FDMT) Short-term Investments (2021 - 2026)

4D Molecular Therapeutics (FDMT) has 6 years of Short-term Investments data on file, last reported at $318.4 million in Q1 2026.

• On a quarterly basis, Short-term Investments rose 69.44% year-over-year to $318.4 million in Q1 2026; TTM through Mar 2026 was $318.4 million, a 69.44% increase from a year earlier, with the FY2025 full-year figure at $342.4 million, up 24.27% from the prior year.
• Short-term Investments for Q1 2026 stood at $318.4 million, down from $342.4 million in the prior quarter.
• Over the last five years, Short-term Investments for FDMT reached as high as $352.9 million in Q2 2024 and fell as low as $39.1 million in Q4 2023.
• Historically, Short-term Investments has averaged $197.8 million across 5 years, with a median of $187.9 million in 2025.
• Across the five-year window, Short-term Investments slumped 75.73% in 2023 and jumped 614.67% in 2024, its largest moves.
• Year by year, Short-term Investments stood at $161.2 million in 2022, then slumped by 75.73% to $39.1 million in 2023, then jumped by 604.28% to $275.5 million in 2024, then advanced by 24.27% to $342.4 million in 2025, then dropped by 7.01% to $318.4 million in 2026.
• Per Business Quant data, the three most recent Short-term Investments figures were $318.4 million in Q1 2026, $342.4 million in Q4 2025, and $256.5 million in Q3 2025.